35.48
-0.64 (-1.77%)
| Previous Close | 36.12 |
| Volume | 181,185 |
| Price / Sales | 438.73 |
| Price / Book | 3.27 |
| 52 Weeks Range |
| Operating Margin (TTM) | -9,701.19% |
| Diluted EPS (TTM) | -4.36 |
| Total Debt/Equity (MRQ) | 4.01% |
| Current Ratio (MRQ) | 21.03 |
| Operating Cash Flow (TTM) | -69.73 M |
| Levered Free Cash Flow (TTM) | -40.39 M |
| Return on Assets (TTM) | -21.97% |
| Return on Equity (TTM) | -34.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Neurogene Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | -2.17 |
|
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.28% |
| % Held by Institutions | 115.82% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Casdin Capital, Llc | 30 Jun 2026 | 1,545,361 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |